International Journal of Radiation Oncology*Biology*Physics
Clinical investigation: head and neckPrediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18f]fluoro-2-deoxy-d-glucose☆
Introduction
According to tumor stage, the treatment of head-and-neck carcinoma is based upon radical radiotherapy (RT) or surgery or both, with or without chemotherapy. While locoregional disease control can be achieved in most patients, failure above the clavicles occurs in as many as 30%–40% of cases 1, 2. Locally recurrent tumors not only threaten patients' survival but also seriously impair their quality of life, as many such patients will die with symptomatic local tumor progression. Moreover, patients with advanced disease are submitted to intensive treatment combinations, and those who are destined to relapse suffer from severe acute toxicity with little benefit (3). Despite careful evaluation of the traditional clinical factors such as tumor size/stage, lymph node involvement, and anatomic subsite, it is impossible to reliably predict the outcome after a selected treatment (4). Identification of novel pretreatment factors that potentially predict outcome is thus of great interest. Patients whose prognoses are likely to be unfavorable with current approaches might be selected for alternative strategies, either by moving away from single-modality therapy to multidisciplinary approaches, by intensifying radiochemotherapy schedules, or by adding innovative biologic agents.
There is increasing current interest in the metabolic imaging of cancers, particularly that based upon tumor uptake of 2-[18F] fluoro-2-deoxy-D-glucose (FDG) as measured by positron emission tomography (PET). This noninvasive imaging technique has been applied to the staging and follow-up of patients with head-and-neck carcinomas as well as other tumor types 5, 6. Furthermore, it has been suggested that tumor FDG uptake may have prognostic significance, in that patients with high FDG uptake generally have a less favorable outcome 7, 8, 9. However, most clinical reports have been based on limited series of patients selected for treatment either with predominantly surgical 7, 8 or nonsurgical (10) approaches. As a consequence it is unknown whether the predictive value of FDG uptake pertains to the response to specific therapies, or rather might reflect the biologic aggressiveness of the disease, independently of the chosen modality. The present study was undertaken to assess the prognostic value of the FDG uptake in unselected series of patients who took part in a prospective study of PET scanning in head-and-neck cancers whatever the treatment they received. The standardized uptake value (SUV), a semiquantitative measurement of tumor FDG uptake, was correlated with local control (LC) and disease free-survival (DFS).
Section snippets
Patients
Patients enrolled in a prospective PET scanning study (11), aiming at optimizing diagnostic evaluation and posttreatment follow-up, form the basis of this analysis. Patient selection and study design were previously described (10). Briefly, participation was solicited of all patients presenting with a suspicious lesion of the head-and-neck region. The study was approved by a Geneva University Hospital ethics committee, and patients were enrolled after signed informed consent was obtained. In
Overall results
Median follow-up for surviving patients was 48 months (range, 7–66 months). Seventy-one patients were alive at last follow-up and 49 had died (37 from head-and-neck cancer, 5 from second cancers, 1 from complications of treatment, and 6 from intercurrent disease). Forty-six patients presented with at least 1 event (32 locally or regionally persistent, or both, or recurrent disease and 20 distant metastases). At 4 years actuarial LC was 75% (95% confidence interval [CI], 67%–84%), DFS was 59%
Discussion
Positron emission tomography imaging represents an area of very active research in oncology. Besides providing useful diagnostic information regarding pretreatment staging and posttreatment follow-up 5, 14, intensity of FDG uptake is emerging as a valuable predictive factor regarding treatment outcome 7, 9. In a previous analysis we have shown that high FDG uptake, as measured by the SUV, was correlated with lower LC and DFS in patients treated by radiotherapy with or without chemotherapy for
Acknowledgements
The authors thank Professor John M. Kurtz, Division of Radiation Oncology, University Hospital, Geneva, Switzerland, for reviewing the manuscript.
References (24)
- et al.
Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer
Int J Radiat Oncol Biol Phys
(2001) - et al.
Accelerated fractionation (AF) compared with conventional fractionation (CF) improves locoregional control in the radiotherapy of advanced head and neck cancersResults of the EORTC 22851 randomized trial
Radiother Oncol
(1997) - et al.
Combined concomitant boost radiotherapy and chemotherapy in stage III-IV head and neck carcinomasA comparison of toxicity and treatment results with those observed after radiotherapy alone
Ann Oncol
(1997) - et al.
Surfing prognostic factors in head and neck cancer at the millennium
Oral Oncol
(1999) - et al.
Avoidance of treatment interruptionAn unrecognized benefit of accelerated radiotherapy in oropharyngeal carcinomas?
Int J Radiat Oncol Biol Phys
(1999) - et al.
Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma
J Clin Oncol
(2002) - et al.
Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on patient managementFirst year's experience in a clinical center
J Clin Oncol
(2001) - et al.
Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancerAn analysis of 125 cases. Leuven Lung Cancer Group
J Clin Oncol
(1999) - et al.
FDG-PET. A possible prognostic factor in head and neck cancer
Br J Cancer
(2002) - et al.
Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro [18F]-D-glucose
Cancer
(1998)
The standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy
J Clin Oncol
Value of positron emission tomography with 18-fluorodeoxyglucose (FDG-PET) in early detection of residual tumor in oro-pharyngeal-laryngeal carcinoma
Schweiz Med Wochenschr
Cited by (0)
- ☆
This work was supported by the Swiss National Science Foundation (Grant no. 31–45955.95).